Home › Companies › Beam Therapeutics Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Beam Therapeutics Inc.’s Form 8-K, filed 2026-06-08 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Beam Therapeutics Inc. in the interactive database Compare manager voting policies
These tallies are Beam Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: John Evans | 71,684,417 | 864,042 | 256,889 | -- | 13,419,659 | Majority: yes |
| Elect Director: John Maraganore, Ph.D. | 64,846,080 | 7,701,591 | 257,677 | -- | 13,419,659 | Majority: yes |
| Elect Director: Christi Shaw | 65,652,959 | 6,893,102 | 259,287 | -- | 13,419,659 | Majority: yes |
| Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 was ratified, based on the following votes: | 85,754,272 | 165,746 | 304,989 | -- | -- | Passed |
| Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes: | 71,546,749 | 985,066 | 273,533 | -- | 13,419,659 | Passed |
Source: Beam Therapeutics Inc., Form 8-K, filed with the SEC on 2026-06-08 — read the filing on EDGAR.
Each item below shows how the 287 asset managers that disclosed a Beam Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99% Passed · of votes cast
Beam Therapeutics Inc.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis, based on the following votes:”): 71,546,749 for, 985,066 against — passed, per its Form 8-K filed 2026-06-08 (Item 5.07). Of all 102,741,848 outstanding shares: 70% for, 1.0% against (71% of the company cast a for/against vote).
The 286 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 13,554,676 | 0 | 0 | 0 | For |
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 9,732,064 | 1 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 6,441,267 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 4,540,132 | 0 | 0 | 0 | For |
| BlackRock | 4,327,035 | 11,751 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 3,822,389 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,089,377 | 0 | 0 | 0 | For |
| State Street | 2,987,409 | 20,386 | 0 | 0 | For |
| Charles Schwab | 1,617,244 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 1,570,747 | 0 | Abstain |
| GEODE CAPITAL MANAGEMENT, LLC | 1,551,483 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 1,164,259 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,139,443 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,000,000 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 628,903 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 570,394 | 0 | 0 | 0 | For |
| Contrarius Group Holdings Ltd | 526,865 | 0 | 0 | 0 | For |
| Northern Trust | 515,351 | 9,721 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 393,142 | 0 | 0 | 0 | For |
| Two Sigma | 350,318 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| American Century | 0 | 336,909 | 0 | 0 | Against |
| GV Management Company, L.L.C. | 321,603 | 0 | 0 | 0 | For |
| Goldman Sachs | 302,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 286 asset managers. See all 286 in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: Christi Shaw”): 65,652,959 for, 6,893,102 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 102,741,848 outstanding shares: 64% for, 7% against (71% of the company cast a for/against vote).
The 67 asset managers below cast 97% of the shares they voted on this item FOR (32,535,732 for, 906,587 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,899,217 | 16 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,849,201 | 2,166 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| Brighthouse | 124,164 | 19,150 | 29,911 | 0 | For |
| American Century | 0 | 168,022 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| First Trust | 0 | 135,021 | 0 | 0 | Against |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 0 | 95,136 | 0 | 0 | Against |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 71,834 | 16,344 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 68,420 | 0 | 0 | Against |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 50,397 | 0 | 0 | Against |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Evans”): 71,684,417 for, 864,042 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 102,741,848 outstanding shares: 70% for, 0.9% against (71% of the company cast a for/against vote).
The 67 asset managers below cast 99.3% of the shares they voted on this item FOR (33,233,427 for, 208,890 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,890,913 | 8,318 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,848,951 | 2,416 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| Brighthouse | 143,314 | 0 | 29,911 | 0 | For |
| American Century | 168,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| First Trust | 135,021 | 0 | 0 | 0 | For |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 95,136 | 0 | 0 | 0 | For |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 84,994 | 3,184 | 0 | 0 | For |
| AIG/SunAmerica | 68,420 | 0 | 0 | 0 | For |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 50,397 | 0 | 0 | 0 | For |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 4 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Beam Therapeutics Inc.’s own tally for this item (“Elect Director: John Maraganore, Ph.D.”): 64,846,080 for, 7,701,591 against, per its Form 8-K filed 2026-06-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 102,741,848 outstanding shares: 63% for, 7% against (71% of the company cast a for/against vote).
The 67 asset managers below cast 97% of the shares they voted on this item FOR (32,468,968 for, 973,349 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,890,898 | 8,333 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,846,785 | 4,582 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 178,015 | 69,200 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| Brighthouse | 124,164 | 19,150 | 29,911 | 0 | For |
| American Century | 0 | 168,022 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| First Trust | 0 | 135,021 | 0 | 0 | Against |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 0 | 95,136 | 0 | 0 | Against |
| Dimensional | 0 | 92,406 | 0 | 0 | Against |
| Lincoln Financial | 71,834 | 16,344 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 68,420 | 0 | 0 | Against |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 50,397 | 0 | 0 | Against |
| Northern Trust | 0 | 44,362 | 0 | 0 | Against |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Passed · of votes cast
Beam Therapeutics Inc.’s own tally for this item (“Proposal 2: The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 was ratified, based on the following votes:”): 85,754,272 for, 165,746 against — passed, per its Form 8-K filed 2026-06-08 (Item 5.07). Of all 102,741,848 outstanding shares: 83% for, 0.2% against (84% of the company cast a for/against vote).
The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (33,441,548 for, 770 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARK ETF Trust | 10,432,026 | 0 | 0 | 0 | For |
| Vanguard | 8,899,232 | 0 | 0 | 0 | For |
| Fidelity | 5,159,735 | 0 | 0 | 0 | For |
| BlackRock | 2,218,373 | 0 | 0 | 0 | For |
| State Street | 1,850,597 | 770 | 0 | 0 | For |
| T. Rowe Price | 1,263,414 | 0 | 0 | 0 | For |
| Charles Schwab | 808,304 | 0 | 0 | 0 | For |
| ARK Venture Fund | 337,310 | 0 | 0 | 0 | For |
| Equitable | 247,215 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 223,757 | 0 | 0 | 0 | For |
| TIAA | 221,207 | 0 | 0 | 0 | For |
| Brighthouse | 143,314 | 0 | 29,911 | 0 | For |
| American Century | 168,022 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 155,367 | 0 | 0 | 0 | For |
| First Trust | 135,021 | 0 | 0 | 0 | For |
| JPMorgan | 128,586 | 0 | 0 | 0 | For |
| ProShares | 95,136 | 0 | 0 | 0 | For |
| Dimensional | 92,406 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,178 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 68,420 | 0 | 0 | 0 | For |
| Russell Investments | 65,283 | 0 | 0 | 0 | For |
| Transamerica | 60,019 | 0 | 0 | 0 | For |
| Global X | 55,500 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 50,397 | 0 | 0 | 0 | For |
| Northern Trust | 44,362 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Ranked by the number of Beam Therapeutics Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 102,741,848 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 13.19% |
| 2 | ARK ETF Trust | 10.15% |
| 3 | Vanguard | 9.47% |
| 4 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 6.27% |
| 5 | ARCH Venture Management, LLC | 4.42% |
| 6 | BlackRock | 4.22% |
| 7 | Amova Asset Management Co., Ltd. | 3.72% |
| 8 | T. Rowe Price | 3.01% |
| 9 | State Street | 2.93% |
| 10 | Charles Schwab | 1.57% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR LLC and affiliates | 12.41% | DEF14A |
| FMR (Fidelity) | 12.12% | 13F |
| Farallon Capital Management, L.L.C. | 10.01% | 13G |
| ARK Investment Management LLC | 9.96% | 13G |
| Farallon Capital Partners LP and affiliates | 9.87% | DEF14A |
| Vanguard Group | 8.95% | 13F |
| BlackRock | 8.26% | 13F |
| STATE STREET CORPORATION | 5.09% | 13G |
| T. Rowe Price | 2.64% | 13F |
| Dimensional Fund Advisors | 2.10% | 13F |
Percentages above are of 102,741,848 shares outstanding, as reported by Beam Therapeutics Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Beam Therapeutics Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Beam Therapeutics Inc.'s shareholder meeting held 2026-06-03, in the 2025-2026 proxy season, 287 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,517 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — the proposal passed with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Beam Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-08.
Beam Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).